What is the enterprise value (EV) for Alnylam Pharmaceuticals, Inc. (ALNY)?

The enterprise value (EV) for ALNY stock is $31.08B.

Alnylam Pharmaceuticals (ALNY) Enterprise Value: History & Chart

Compare

Alnylam Pharmaceuticals, Inc.(ALNY)

Biotechnology · Cambridge, MA

$237.10+0.54 (+0.23%)

At close: Aug 28, 2026, 4:00 PM ET

Compare

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

2,500 employees

www.alnylam.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Yvonne L. Greenstreet

View full financials

NAME	MARKET CAP	ENTERPRISE VALUE (EV)
Alnylam Pharmaceuticals, Inc. (ALNY)	$31.73B	$31.08B
Centene Corp. (CNC)vs ›	$31.99B	$23.94B
Biogen Inc. (BIIB)vs ›	$32.28B	$39.35B
GE HealthCare Technologies Inc. (GEHC)vs ›	$32.40B	$40.39B
Zoetis Inc. (ZTS)vs ›	$32.42B	$40.19B
Waters Corporation (WAT)vs ›	$31.02B	$35.73B
Medline Inc. (MDLN)vs ›	$29.83B	$40.15B
DexCom, Inc. (DXCM)vs ›	$34.27B	$34.57B
ResMed Inc. (RMD)vs ›	$34.86B	$34.22B
Alcon Inc. (ALC)vs ›	$35.12B	$39.06B

NAME

MARKET CAP

ENTERPRISE VALUE (EV)

Alnylam Pharmaceuticals, Inc. (ALNY)

$31.73B

$31.08B

Centene Corp. (CNC)vs ›

$31.99B

$23.94B

Biogen Inc. (BIIB)vs ›

$32.28B

$39.35B